JPH0245461B2 - - Google Patents
Info
- Publication number
- JPH0245461B2 JPH0245461B2 JP58159076A JP15907683A JPH0245461B2 JP H0245461 B2 JPH0245461 B2 JP H0245461B2 JP 58159076 A JP58159076 A JP 58159076A JP 15907683 A JP15907683 A JP 15907683A JP H0245461 B2 JPH0245461 B2 JP H0245461B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- pulse
- conductor
- current
- iontophoresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004020 conductor Substances 0.000 claims description 67
- 230000007246 mechanism Effects 0.000 claims description 44
- 230000010355 oscillation Effects 0.000 claims description 21
- 230000028161 membrane depolarization Effects 0.000 claims description 10
- 210000003491 skin Anatomy 0.000 description 57
- 239000000499 gel Substances 0.000 description 51
- 229940079593 drug Drugs 0.000 description 38
- 239000003814 drug Substances 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 238000010586 diagram Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000003990 capacitor Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000010287 polarization Effects 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 8
- 239000011505 plaster Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- -1 gauze Substances 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000002999 depolarising effect Effects 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960003712 propranolol Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 229920000569 Gum karaya Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000934878 Sterculia Species 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000231 karaya gum Substances 0.000 description 3
- 235000010494 karaya gum Nutrition 0.000 description 3
- 229940039371 karaya gum Drugs 0.000 description 3
- 239000000025 natural resin Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 206010008570 Chloasma Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 2
- 229950006991 betamethasone phosphate Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 101100070120 Xenopus laevis has-rs gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006359 acetalization reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007772 electrode material Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Electrotherapy Devices (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15907683A JPS60156475A (ja) | 1983-09-01 | 1983-09-01 | イオントフォレ−ゼ用デバイス |
| CA000461979A CA1262564A (en) | 1983-09-01 | 1984-08-28 | Iontophoresis device |
| DE8484305910T DE3479191D1 (en) | 1983-09-01 | 1984-08-29 | An iontophoresis device |
| EP84305910A EP0138347B1 (en) | 1983-09-01 | 1984-08-29 | An iontophoresis device |
| DE3486412T DE3486412T2 (de) | 1983-09-01 | 1984-08-29 | Iontophoresegerät. |
| AU32492/84A AU575068B2 (en) | 1983-09-01 | 1984-08-29 | Iontophoresis device |
| EP88103452A EP0308572B1 (en) | 1983-09-01 | 1984-08-29 | An iontophoresis device |
| US06/792,245 US4764164A (en) | 1983-09-01 | 1985-10-30 | Iontophoresis device |
| AU18506/88A AU599493B2 (en) | 1983-09-01 | 1988-06-29 | An iontophoresis device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15907683A JPS60156475A (ja) | 1983-09-01 | 1983-09-01 | イオントフォレ−ゼ用デバイス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4118590A Division JPH02243168A (ja) | 1990-02-23 | 1990-02-23 | イオントフォレーゼ用デバイス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60156475A JPS60156475A (ja) | 1985-08-16 |
| JPH0245461B2 true JPH0245461B2 (zh) | 1990-10-09 |
Family
ID=15685690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15907683A Granted JPS60156475A (ja) | 1983-09-01 | 1983-09-01 | イオントフォレ−ゼ用デバイス |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60156475A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010137048A (ja) * | 2008-11-14 | 2010-06-24 | Tokyo Institute Of Technology | イオントフォレシス用電極組成物 |
| JP2010148979A (ja) * | 2010-04-05 | 2010-07-08 | Kyushu Hitachi Maxell Ltd | イオン導入器 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62133972A (ja) * | 1985-12-04 | 1987-06-17 | 株式会社アドバンス | 小型低周波治療器 |
| JPH0817822B2 (ja) * | 1986-11-11 | 1996-02-28 | 久光製薬株式会社 | 小型低周波治療器 |
| JPS6322940U (zh) * | 1986-07-30 | 1988-02-15 | ||
| JPH064096B2 (ja) * | 1987-03-25 | 1994-01-19 | 株式会社アドバンス | 皮膚貼着型低周波治療器 |
| JPH0436839Y2 (zh) * | 1987-05-27 | 1992-08-31 | ||
| JPH0197475A (ja) * | 1987-10-09 | 1989-04-14 | Watanabe Wataru | 電気治療器 |
| JP2782195B2 (ja) * | 1988-04-30 | 1998-07-30 | 日東電工株式会社 | イオントフォレーゼ用電気回路 |
| JPH0190559U (zh) * | 1988-12-16 | 1989-06-14 | ||
| JPH0659322B2 (ja) * | 1992-04-04 | 1994-08-10 | 久光製薬株式会社 | 皮膚貼着型低周波治療器 |
| JP4079481B2 (ja) | 1997-06-27 | 2008-04-23 | 久光製薬株式会社 | 経皮または経粘膜薬物送達用デバイス |
| US8190252B2 (en) | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
| US9008765B2 (en) | 2009-02-12 | 2015-04-14 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
| WO2011044175A2 (en) | 2009-10-06 | 2011-04-14 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
| JP5780666B2 (ja) * | 2011-01-25 | 2015-09-16 | 日立マクセル株式会社 | 美容装置 |
| CN106955415B (zh) | 2011-03-24 | 2019-06-18 | 因卡伯实验室有限责任公司 | 用于治疗剂的两阶段经皮离子电渗递送的系统及方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5554961A (en) * | 1978-10-18 | 1980-04-22 | Tapper Robert | Method that apply ion osmosis treatment method and its device |
| JPS5810066A (ja) * | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | イオントフオレ−ゼ用プラスタ−構造体 |
-
1983
- 1983-09-01 JP JP15907683A patent/JPS60156475A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5554961A (en) * | 1978-10-18 | 1980-04-22 | Tapper Robert | Method that apply ion osmosis treatment method and its device |
| JPS5810066A (ja) * | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | イオントフオレ−ゼ用プラスタ−構造体 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010137048A (ja) * | 2008-11-14 | 2010-06-24 | Tokyo Institute Of Technology | イオントフォレシス用電極組成物 |
| JP2010148979A (ja) * | 2010-04-05 | 2010-07-08 | Kyushu Hitachi Maxell Ltd | イオン導入器 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60156475A (ja) | 1985-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4764164A (en) | Iontophoresis device | |
| JP3119486B2 (ja) | イオントフォレーシス用電極及びそれを用いたデバイス | |
| JP4165659B2 (ja) | 安全性が改良され、乱用可能性が低下した電気的移送式投与デバイス | |
| JPH0245461B2 (zh) | ||
| US4474570A (en) | Iontophoresis device | |
| EP0705619B1 (en) | Iontophoresis device | |
| AU637674B2 (en) | Method and apparatus for pulsed iontophoretic drug delivery | |
| US5006108A (en) | Apparatus for iontophoretic drug delivery | |
| KR20040053184A (ko) | 피부 패치 | |
| JPH11507274A (ja) | 電気的移送式作用剤投与方法と装置 | |
| JPH05506165A (ja) | イオン導入用送出装置 | |
| JPS6329662A (ja) | 経皮的薬物投与装置 | |
| JP2000510012A (ja) | イオン導入法による薬剤の供給装置およびその使用方法 | |
| WO1992004937A1 (en) | Iontophoretic drug delivery apparatus | |
| EP0308572B1 (en) | An iontophoresis device | |
| WO2007106270A2 (en) | Stimulating galvanic or slow ac current for therapeutic physiological effects | |
| US20100228180A1 (en) | Power Source Electrode Treatment Device | |
| JP2816886B2 (ja) | 生体通電装置 | |
| JPH04224770A (ja) | イオントフォレーシス用装置 | |
| JPH0852224A (ja) | イオントフォレーシス用デバイス | |
| JP2839279B2 (ja) | イオントフォレーゼ用デバイス | |
| JPH0349589B2 (zh) | ||
| JPS60188176A (ja) | イオントフオレ−ゼ用デバイス | |
| JPH0217187B2 (zh) | ||
| JPH041634B2 (zh) |